Generic Auvelity Availability

Last updated on May 7, 2025.

Auvelity is a brand name of bupropion/dextromethorphan, approved by the FDA in the following formulation(s):

AUVELITY (bupropion hydrochloride; dextromethorphan hydrobromide - tablet, extended release;oral)

• Manufacturer: AXSOME
  Approval date: August 18, 2022
  Strength(s): 105MG;45MG ^[RLD]

Is there a generic version of Auvelity available?

No. There is currently no therapeutically equivalent version of Auvelity available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Auvelity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Bupropion as a modulator of drug activity
  Patent 10,058,518
  Issued: August 28, 2018
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,064,857
  Issued: September 4, 2018
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 10,080,727
  Issued: September 25, 2018
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 10,092,560
  Issued: October 9, 2018
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
  Patent 10,092,561
  Issued: October 9, 2018
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
  Patent 10,105,327
  Issued: October 23, 2018
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 10,105,361
  Issued: October 23, 2018
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,251,879
  Issued: April 9, 2019
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 10,463,634
  Issued: November 5, 2019
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 10,512,643
  Issued: December 24, 2019
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 10,548,857
  Issued: February 4, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
  Patent 10,596,167
  Issued: March 24, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,772,850
  Issued: September 15, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,780,064
  Issued: September 22, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • January 7, 2040
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 10,780,066
  Issued: September 22, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 9, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 10,786,469
  Issued: September 29, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 10,786,496
  Issued: September 29, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Combination of dextromethorphan and bupropion for treating depression
  Patent 10,799,497
  Issued: October 13, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,806,710
  Issued: October 20, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,864,209
  Issued: December 15, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,874,663
  Issued: December 29, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,874,664
  Issued: December 29, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,874,665
  Issued: December 29, 2020
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 10,881,624
  Issued: January 5, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,881,657
  Issued: January 5, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,894,046
  Issued: January 19, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,894,047
  Issued: January 19, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,898,453
  Issued: January 26, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,925,842
  Issued: February 23, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • January 7, 2040
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,933,034
  Issued: March 2, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,940,124
  Issued: March 9, 2021
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • January 7, 2040
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,945,973
  Issued: March 16, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,966,941
  Issued: April 6, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLP
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,966,942
  Issued: April 6, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • January 7, 2040
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 10,966,974
  Issued: April 6, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,020,389
  Issued: June 1, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,058,648
  Issued: July 13, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): Antecip Bioventures II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,090,300
  Issued: August 17, 2021
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,096,937
  Issued: August 24, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,123,343
  Issued: September 21, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,129,826
  Issued: September 28, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): AXSOME THERAPEUTICS, INC.
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,141,388
  Issued: October 12, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,141,416
  Issued: October 12, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): Antecip Bioventures II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Method of decreasing the fluctuation index of dextromethorphan
  Patent 11,147,808
  Issued: October 19, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,185,515
  Issued: November 30, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,191,739
  Issued: December 7, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
    ✓ 
    Drug product
• Bupropion as a modulator of drug activity
  Patent 11,197,839
  Issued: December 14, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
    ✓ 
    Drug product
• Bupropion as a modulator of drug activity
  Patent 11,207,281
  Issued: December 28, 2021
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,213,521
  Issued: January 4, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Combination of dextromethorphan and bupropion for treating depression
  Patent 11,229,640
  Issued: January 25, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,234,946
  Issued: February 1, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,253,491
  Issued: February 22, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,253,492
  Issued: February 22, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,273,133
  Issued: March 15, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, methods related to sustained release of dextromethorphan or improved therapeutic effects. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,273,134
  Issued: March 15, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,285,118
  Issued: March 29, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,285,146
  Issued: March 29, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,291,638
  Issued: April 5, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,291,665
  Issued: April 5, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,298,351
  Issued: April 12, 2022
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,298,352
  Issued: April 12, 2022
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,311,534
  Issued: April 26, 2022
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIO VENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,344,544
  Issued: May 31, 2022
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,357,744
  Issued: June 14, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,364,233
  Issued: June 21, 2022
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,382,874
  Issued: July 12, 2022
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,419,867
  Issued: August 23, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,426,370
  Issued: August 30, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,426,401
  Issued: August 30, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,433,067
  Issued: September 6, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
    ✓ 
    Drug product
• Bupropion as a modulator of drug activity
  Patent 11,439,636
  Issued: September 13, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,478,468
  Issued: October 25, 2022
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,497,721
  Issued: November 15, 2022
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,510,918
  Issued: November 29, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,517,542
  Issued: December 6, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,517,543
  Issued: December 6, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,524,007
  Issued: December 13, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,524,008
  Issued: December 13, 2022
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,534,414
  Issued: December 27, 2022
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
    ✓ 
    Drug product
• Bupropion as a modulator of drug activity
  Patent 11,541,021
  Issued: January 3, 2023
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,541,048
  Issued: January 3, 2023
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,596,627
  Issued: March 7, 2023
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,617,728
  Issued: April 4, 2023
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,617,747
  Issued: April 4, 2023
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO INCREASE DEXTROMETHORPHAN PLASMA LEVELS
• Bupropion dosage forms with reduced food and alcohol dosing effects
  Patent 11,717,518
  Issued: August 8, 2023
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

  Patent expiration dates:

  • January 20, 2043
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Treatment of depression in certain patient populations
  Patent 11,730,706
  Issued: August 22, 2023
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prologation.

  Patent expiration dates:

  • January 23, 2043
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compounds and combinations thereof for treating neurological and psychiatric conditions
  Patent 11,752,144
  Issued: September 12, 2023
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

  Patent expiration dates:

  • February 23, 2043
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,779,579
  Issued: October 10, 2023
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compounds and combinations thereof for treating neurological and psychiatric conditions
  Patent 11,839,612
  Issued: December 12, 2023
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

  Patent expiration dates:

  • March 2, 2043
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Combination of dextromethorphan and bupropion for treating depression
  Patent 11,844,797
  Issued: December 19, 2023
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients having mild or moderate hepatic impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

  Patent expiration dates:

  • April 20, 2043
    
    ✓ 
    Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER BY ADMINISTERING DEXTROMETHORPHAN AND BUPROPION TO A SUBJECT HAVING MODERATE HEPATIC IMPAIRMENT
• Treatment of depression in certain patient populations
  Patent 11,883,373
  Issued: January 30, 2024
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prologation.

  Patent expiration dates:

  • January 23, 2043
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion and dextromethorphan for reduction of suicide risk in depression patients
  Patent 11,896,563
  Issued: February 13, 2024
  Inventor(s): Tabuteau; Herriot
  Assignee(s): Antecip Bioventures II LLC (New York, NY)
  

  This disclosure relates to a method of treating depression and/or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

  Patent expiration dates:

  • December 1, 2041
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion dosage forms with reduced food and alcohol dosing effects
  Patent 11,925,636
  Issued: March 12, 2024
  Inventor(s): Tabuteau; Herriot
  Assignee(s): Antecip Bioventures II LLC (New York, NY)
  

  This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

  Patent expiration dates:

  • January 20, 2043
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 11,969,421
  Issued: April 30, 2024
  Inventor(s): Tabuteau; Herriot
  Assignee(s): Antecip Bioventures II LLC (New York, NY)
  

  Disclosed herein are methods of treating neurological or psychiatric diseases or disorders using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
  Patent 11,986,444
  Issued: May 21, 2024
  Inventor(s): Tabuteau; Herriot
  Assignee(s): Antecip Bioventures II LLC (New York, NY)
  

  Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

  Patent expiration dates:

  • February 15, 2043
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
  Patent 12,036,191
  Issued: July 16, 2024
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

  Patent expiration dates:

  • February 15, 2043
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compounds and combinations thereof for treating neurological and psychiatric conditions
  Patent 12,042,473
  Issued: July 23, 2024
  Inventor(s): Tabuteau; Herriot
  Assignee(s): Antecip Bioventures II LLC (New York, NY)
  

  This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

  Patent expiration dates:

  • February 23, 2043
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 12,109,178
  Issued: October 8, 2024
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compounds and combinations thereof for treating neurological and psychiatric conditions
  Patent 12,146,889
  Issued: November 19, 2024
  Inventor(s): Tabuteau; Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC (New York, NY)
  

  This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

  Patent expiration dates:

  • February 23, 2043
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Pharmaceutical compositions comprising bupropion and cysteine
  Patent 12,156,914
  Issued: December 3, 2024
  Inventor(s): Tabuteau; Herriot
  Assignee(s): AXSOME THERAPEUTICS, INC. (New York, NY)
  

  This disclosure relates to pharmaceutical compositions comprising bupropion and cysteine, and pharmaceutical dosage forms comprising bupropion and cysteine. The disclosure also relates to molecular complexes of bupropion and cysteine. These compositions and dosage forms may have improved stability of bupropion.

  Patent expiration dates:

  • January 20, 2043
    
    ✓ 
    Drug product
• Compositions and methods comprising tilidine or related compounds and dextromethorphan
  Patent 8,569,328
  Issued: October 29, 2013
  Inventor(s): Tabuteau Herriot
  Assignee(s): Antecip Bioventures II LLC
  

  Pain and/or neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound such as tilidine that inhibits the cytochrome P450 isozyme CYP2D6, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein.

  Patent expiration dates:

  • October 29, 2033
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
    ✓ 
    Drug product
• Bupropion as a modulator of drug activity
  Patent 9,168,234
  Issued: October 27, 2015
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
  Patent 9,198,905
  Issued: December 1, 2015
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods of decreasing dextrorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
  Patent 9,205,083
  Issued: December 8, 2015
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods of improving the efficacy of dextromethorphan, or providing beneficial pharmacokinetic effects to dextromethorphan, comprising co-administering erythrohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
  Patent 9,238,032
  Issued: January 19, 2016
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 9,278,095
  Issued: March 8, 2016
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects
  Patent 9,314,462
  Issued: April 19, 2016
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods of increasing dextromethorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 9,370,513
  Issued: June 21, 2016
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods of increasing the metabolic lifetime of dextromethorphan administering threohydroxybupropion or bupropion to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and threohydroxybupropion or bupropion are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
  Patent 9,375,429
  Issued: June 28, 2016
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods of improving the efficacy of dextromethorphan, or providing beneficial pharmacokinetic effects to dextromethorphan, comprising co-administering erythrohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Bupropion as a modulator of drug activity
  Patent 9,408,815
  Issued: August 9, 2016
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 9,421,176
  Issued: August 23, 2016
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods of increasing dextromethorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 9,457,023
  Issued: October 4, 2016
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
  Patent 9,457,025
  Issued: October 4, 2016
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 9,474,731
  Issued: October 25, 2016
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Hydroxybupropion and related compounds as modulators of drug plasma levels
  Patent 9,486,450
  Issued: November 8, 2016
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering hydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and hydroxybupropion or a prodrug of hydroxybupropion are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 9,700,528
  Issued: July 11, 2017
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 9,700,553
  Issued: July 11, 2017
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 9,707,191
  Issued: July 18, 2017
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 9,763,932
  Issued: September 19, 2017
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 9,861,595
  Issued: January 9, 2018
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 9,867,819
  Issued: January 16, 2018
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
• Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
  Patent 9,968,568
  Issued: May 15, 2018
  Inventor(s): Tabuteau Herriot
  Assignee(s): ANTECIP BIOVENTURES II LLC
  

  This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

  Patent expiration dates:

  • November 5, 2034
    
    ✓ 
    Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • August 18, 2025 - NEW PRODUCT

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer